ARQ 621 |
An Eg5 inhibitor; reduces tumor growth in a MIA PaCa-2 pancreatic cancer m… |
1 mg |
34329-1 |
More Info
|
ARQ 621 |
An Eg5 inhibitor; reduces tumor growth in a MIA PaCa-2 pancreatic cancer m… |
10 mg |
34329-10 |
More Info
|
ARQ 621 |
An Eg5 inhibitor; reduces tumor growth in a MIA PaCa-2 pancreatic cancer m… |
25 mg |
34329-25 |
More Info
|
ARQ 621 |
An Eg5 inhibitor; reduces tumor growth in a MIA PaCa-2 pancreatic cancer m… |
5 mg |
34329-5 |
More Info
|
ARQ-092 |
A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5… |
1 mg |
21388-1 |
More Info
|
ARQ-092 |
A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5… |
10 mg |
21388-10 |
More Info
|
ARQ-092 |
A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5… |
25 mg |
21388-25 |
More Info
|
ARQ-092 |
A selective, allosteric, orally bioavailable, pan-Akt inhibitor (IC50s = 5… |
5 mg |
21388-5 |
More Info
|
ARQ 531 |
A BTK inhibitor (IC50 = 0.85 nM); reduces the viability of, and inhibits B… |
1 mg |
30165-1 |
More Info
|
ARQ 531 |
A BTK inhibitor (IC50 = 0.85 nM); reduces the viability of, and inhibits B… |
10 mg |
30165-10 |
More Info
|
ARQ 531 |
A BTK inhibitor (IC50 = 0.85 nM); reduces the viability of, and inhibits B… |
25 mg |
30165-25 |
More Info
|
ARQ 531 |
A BTK inhibitor (IC50 = 0.85 nM); reduces the viability of, and inhibits B… |
5 mg |
30165-5 |
More Info
|
(6aR,9R)-11-hydroxy-Δ10-THC |
An analytical reference standard that is structurally similar to known phy… |
1 mg |
38231-1 |
More Info
|
(6aR,9R)-11-hydroxy-Δ10-THC |
An analytical reference standard that is structurally similar to known phy… |
100 µg |
38231-100 |
More Info
|
(6aR, 9R)-11-hydroxy-Δ10-THC (exempt preparation) |
An analytical reference standard that is structurally similar to known phy… |
100 µg |
41299-100 |
More Info
|
(6aR,9R)-11-nor-9-carboxy-Δ10-THC |
An analytical reference standard that is structurally similar to known phy… |
1 mg |
38235-1 |
More Info
|
(6aR,9R)-11-nor-9-carboxy-Δ10-THC |
An analytical reference standard that is structurally similar to known phy… |
500 µg |
38235-500 |
More Info
|
ARRY-382 |
A CSF1R inhibitor (IC50 = 9 nM); selective for CSF1R over PDGFR, c-Kit, an… |
1 mg |
38796-1 |
More Info
|
ARRY-382 |
A CSF1R inhibitor (IC50 = 9 nM); selective for CSF1R over PDGFR, c-Kit, an… |
10 mg |
38796-10 |
More Info
|
ARRY-382 |
A CSF1R inhibitor (IC50 = 9 nM); selective for CSF1R over PDGFR, c-Kit, an… |
5 mg |
38796-5 |
More Info
|
ARRY-520 |
A potent Eg5 inhibitor (IC50 = 6 nM); selective for Eg5 over a panel of 8… |
1 mg |
21883-1 |
More Info
|
ARRY-520 |
A potent Eg5 inhibitor (IC50 = 6 nM); selective for Eg5 over a panel of 8… |
10 mg |
21883-10 |
More Info
|
ARRY-520 |
A potent Eg5 inhibitor (IC50 = 6 nM); selective for Eg5 over a panel of 8… |
25 mg |
21883-25 |
More Info
|
ARRY-520 |
A potent Eg5 inhibitor (IC50 = 6 nM); selective for Eg5 over a panel of 8… |
5 mg |
21883-5 |
More Info
|
Arry-380 analog |
An inhibitor of EGFR |
1 mg |
24186-1 |
More Info
|